首页> 美国卫生研究院文献>PLoS Clinical Trials >Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies
【2h】

Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies

机译:新型具有小结构的小型有机化合物的鉴定,用于诱导EBV阳性上皮恶性肿瘤中的爱泼斯坦-巴尔病毒(EBV)裂解周期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Phorbol esters, which are protein kinase C (PKC) activators, and histone deacetylase (HDAC) inhibitors, which cause enhanced acetylation of cellular proteins, are the main classes of chemical inducers of Epstein-Barr virus (EBV) lytic cycle in latently EBV-infected cells acting through the PKC pathway. Chemical inducers which induce EBV lytic cycle through alternative cellular pathways may aid in defining the mechanisms leading to lytic cycle reactivation and improve cells’ responsiveness towards lytic induction. We performed a phenotypic screening on a chemical library of 50,240 novel small organic compounds to identify novel class(es) of strong inducer(s) of EBV lytic cycle in gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC) cells. Five hit compounds were selected after three successive rounds of increasingly stringent screening. All five compounds are structurally diverse from each other and distinct from phorbol esters or HDAC inhibitors. They neither cause hyperacetylation of histone proteins nor significant PKC activation at their working concentrations, suggesting that their biological mode of action are distinct from that of the known chemical inducers. Two of the five compounds with rapid lytic-inducing action were further studied for their mechanisms of induction of EBV lytic cycle. Unlike HDAC inhibitors, lytic induction by both compounds was not inhibited by rottlerin, a specific inhibitor of PKCδ. Interestingly, both compounds could cooperate with HDAC inhibitors to enhance EBV lytic cycle induction in EBV-positive epithelial cancer cells, paving way for the development of strategies to increase cells’ responsiveness towards lytic reactivation. One of the two compounds bears structural resemblance to iron chelators and the other strongly activates the MAPK pathways. These structurally diverse novel organic compounds may represent potential new classes of chemicals that can be used to investigate any alternative mechanism(s) leading to EBV lytic cycle reactivation from latency.
机译:酚蛋白酯是蛋白激酶C(PKC)的激活剂,而组蛋白脱乙酰基酶(HDAC)抑制剂则是引起细胞蛋白乙酰化程度提高的原因,它们是EBV-潜伏期中爱泼斯坦-巴尔病毒(EBV)裂解周期的主要化学诱导剂。感染的细胞通过PKC途径起作用。通过其他细胞途径诱导EBV裂解周期的化学诱导剂可能有助于确定导致裂解周期重新激活的机制,并改善细胞对裂解诱导的反应性。我们在50,240种新型小有机化合物的化学文库中进行了表型筛选,以鉴定在胃癌(GC)和鼻咽癌(NPC)细胞中EBV裂解周期强诱导剂的新类别。在连续三轮越来越严格的筛选之后,选择了五个命中化合物。这五种化合物在结构上彼此不同,与佛波酯或HDAC抑制剂不同。它们在其工作浓度下均不会引起组蛋白的过度乙酰化或显着的PKC活化,表明它们的生物学作用模式与已知的化学诱导剂不同。进一步研究了5种具有快速裂解诱导作用的化合物中的2种化合物诱导EBV裂解周期的机理。与HDAC抑制剂不同,两种化合物的裂解诱导均不受rottlerin(一种PKCδ的特异性抑制剂)的抑制。有趣的是,这两种化合物都可以与HDAC抑制剂协同作用,以增强EBV阳性上皮癌细胞中的EBV裂解周期诱导作用,从而为开发提高细胞对裂解再激活反应性的策略铺平了道路。两种化合物之一与铁螯合剂具有结构相似性,另一种则强烈激活MAPK途径。这些结构多样的新型有机化合物可能代表了潜在的新型化学物质,可用于研究导致潜伏期导致EBV裂解循环重新激活的任何其他机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号